China Everbright Limited

China Everbright Limited Announces 2023 Interim Results, Realises Turnaround of Loss to Profit

Retrieved on: 
Friday, August 25, 2023
IPO, Bed, Achaea, Dreams of Divine Lands, Fisher Youngster, Culture, Insurance, CALC, CEL, Health care, HKSAR, Policy, Artificial intelligence of things, TCFD, Attitude, M&A, MSCI, AUM, Investment, Economic development, Artificial intelligence, Guangdong–Hong Kong–Macao Greater Bay Area, City, ESG, Growth, Guangzhou, Digital, Aircraft, China Everbright Limited, Yellow economic circle, Financial adviser, Cryptocurrency, Holding company, Bank, Yangtze Delta

HONG KONG, Aug 25, 2023 - (ACN Newswire) - On 25 August 2023, China Everbright Limited ("CEL" or the "Company", stock code: 165.HK) announced its interim results for the six months ended 30 June 2023 ("the reporting period").

Key Points: 
  • HONG KONG, Aug 25, 2023 - (ACN Newswire) - On 25 August 2023, China Everbright Limited ("CEL" or the "Company", stock code: 165.HK) announced its interim results for the six months ended 30 June 2023 ("the reporting period").
  • -- The overall operating revenue was HK$1.54 billion, representing a steady increase in overall operating results
    -- Profit attributable to shareholders of the Company was HK$313 million, realising a turnaround from loss to profit.
  • To share the fruits of the Company's development with shareholders and investors, the Board of Directors declared interim dividend of HK$0.15 per share for 2023.
  • Mr. Zhang Mingao, Executive Director and President of China Everbright Limited, said: "In the first half of 2023, there was steady recovery in the Chinese economy and a significant upturn.

IASO Biotherapeutics Secures $108 Million Series C Funding to Advance Global Development of Innovative Cell Therapies

Retrieved on: 
Thursday, September 16, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, CD5, Semiconductor, Artificial intelligence, NDA, CEO, Patient, BCMA, Series, Clinical trial, IND, Maxwell, Investment, CDH, RRMM, NMPA, Degenerative disease, CAR, CMO, CDH Investments, Trust, China Everbright Limited, Pharmaceutical industry, Fine chemical, CDH Baifu, IASO Bio, CDH BAIFU, IASO BIO

IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company focusing on discovering, developing, and manufacturing innovative medicines, today announced the completion of $108 million Series C to advance the global development of novel cell therapies and biologics for oncology and autoimmune diseases.

Key Points: 
  • IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company focusing on discovering, developing, and manufacturing innovative medicines, today announced the completion of $108 million Series C to advance the global development of novel cell therapies and biologics for oncology and autoimmune diseases.
  • Proceeds from the financing will be used to accelerate the global development and regulatory submissions of multiple novel cell therapies.
  • The clinical development of these three innovative products marks the full coverage of our products in plasma cell, B cell, and T cell malignancies.
  • IASO Bio is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases.

Everbright Grand China Announces 2020 Annual Results

Retrieved on: 
Thursday, March 25, 2021
China Everbright Group, Companies of China, Companies, Everbright, Economy of China, Property management, China Everbright Limited, Everbright Sun Hung Kai

HONG KONG, Mar 25, 2021 - (ACN Newswire) - Everbright Grand China Assets Limited ("Everbright Grand China" or the "Group"; HKEX stock code: 03699), a subsidiary of China Everbright Group, principally engaged in the businesses of property leasing, property management and sales of properties held for sale, announced its annual results ended 31 December 2020 ("Reporting Period").

Key Points: 
  • HONG KONG, Mar 25, 2021 - (ACN Newswire) - Everbright Grand China Assets Limited ("Everbright Grand China" or the "Group"; HKEX stock code: 03699), a subsidiary of China Everbright Group, principally engaged in the businesses of property leasing, property management and sales of properties held for sale, announced its annual results ended 31 December 2020 ("Reporting Period").
  • Everbright Grand China Assets Limited, a subsidiary of China Everbright Group, principally engaged in the businesses of property leasing, property management and sales of properties held for sale, owns, leases and manages properties located in Chengdu, Sichuan province, and also owns and leases a property located in Kunming, Yunnan province.
  • For further details regarding to Everbright Grand China Assets Limited, please visit its website at http://ebgca.com.hk/.
  • Issued by Porda Havas International Finance Communications Group for and on behalf of Everbright Grand China Assets Limited.

2018 Everbright Investment Conference Successfully Held in Hangzhou

Retrieved on: 
Wednesday, October 24, 2018
China Everbright Group, Government of China, H shares, Economy of China, Business, China Everbright Limited, Everbright, China Everbright Bank, Everbright Sun Hung Kai, Central Huijin Investment

HANGZHOU, China, Oct. 24, 2018 /PRNewswire/ -- China Everbright Limited ("Everbright", stock code: 165.HK), the flagship overseas investment platform of China Everbright Group, successfully hosted its 7th Everbright Investment Conference at Midtown Shangri-La in Hangzhou, China between 22 and 23 October.

Key Points: 
  • HANGZHOU, China, Oct. 24, 2018 /PRNewswire/ -- China Everbright Limited ("Everbright", stock code: 165.HK), the flagship overseas investment platform of China Everbright Group, successfully hosted its 7th Everbright Investment Conference at Midtown Shangri-La in Hangzhou, China between 22 and 23 October.
  • Held in Hangzhou, one of the six ancient capitals of China, the summit has strong support from the Zhejiang provincial government and Hangzhou City.
  • For more information on the 7th Everbright Investment Conference, please visit the conference website: http://everbright-conference2018.com/
    China Everbright Limited (Everbright, stock code: 165.HK) was established in Hong Kong in 1997 and is China's leading cross-border investment and asset management company.
  • Everbright is the second-largest shareholder of Everbright Securities (stock code: 601788.SH, 6178.HK) and a strategic shareholder of China Everbright Bank (stock code: 601818.SH, 6818.HK).

2018 Everbright Investment Conference Successfully Held in Hangzhou

Retrieved on: 
Wednesday, October 24, 2018
China Everbright Group, Government of China, H shares, Economy of China, China Everbright Limited, Business, Everbright, China Everbright Bank, Everbright Sun Hung Kai, Central Huijin Investment

HANGZHOU, China, Oct. 23, 2018 /PRNewswire/ -- China Everbright Limited ("Everbright", stock code: 165.HK), the flagship overseas investment platform of China Everbright Group, successfully hosted its 7th Everbright Investment Conference at Midtown Shangri-La in Hangzhou, China between 22 and 23 October.

Key Points: 
  • HANGZHOU, China, Oct. 23, 2018 /PRNewswire/ -- China Everbright Limited ("Everbright", stock code: 165.HK), the flagship overseas investment platform of China Everbright Group, successfully hosted its 7th Everbright Investment Conference at Midtown Shangri-La in Hangzhou, China between 22 and 23 October.
  • Held in Hangzhou, one of the six ancient capitals of China, the summit has strong support from the Zhejiang provincial government and Hangzhou City.
  • For more information on the 7th Everbright Investment Conference, please visit the conference website: http://everbright-conference2018.com/
    China Everbright Limited (Everbright, stock code: 165.HK) was established in Hong Kong in 1997 and is China's leading cross-border investment and asset management company.
  • Everbright is the second-largest shareholder of Everbright Securities (stock code: 601788.SH, 6178.HK) and a strategic shareholder of China Everbright Bank (stock code: 601818.SH, 6818.HK).